Search Within

Ellen Marlese Basu

  1. "2019"
Formats
  1. Meeting Abstract (13)
  2. Journal Article (2)
Groups
  1. Neuroblastoma Service (15)
  2. Pediatrics, Department of (15)
  3. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (10)
  4. Center for Molecular Imaging and Biotechnology (CMIB) (10)
  5. GSK Faculty (10)
  6. Tow Center for Developmental Oncology (TCDO) (10)

More Groups

People
  1. Shakeel Modak (11)
  2. Stephen Roberts (11)
  3. Brian Kushner (10)
  4. Nai-Kong Cheung (10)
  5. Audrey Mauguen (4)
  6. Neeta Pandit-Taskar (3)

More People

Years
  1. 2019 (15)
Publications
  1. Pediatric Blood and Cancer (8)
  2. Journal of Clinical Oncology (3)
  3. Neuro-Oncology (2)
  4. International Journal of Radiation Oncology, Biology, Physics (1)
  5. Pediatrics (1)
Publishers
  1. Wiley Periodicals, Inc (8)
  2. American Society of Clinical Oncology (3)
  3. Oxford University Press (2)
  4. American Academy of Pediatrics (1)
  5. Elsevier Inc. (1)

Results (15)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Entrectinib in children and adolescents with recurrent or refractory solid tumors including primary CNS tumors
    Meeting Abstract

    Robinson, G.; Desai, A.; Gauvain, K.; Basu, E.; Dorris, K.; Maese, L.; Sabnis, A.; Foster, J.; Shusterman, S.; Yoon, J.; more...
    Neuro-Oncology (2019)

    Fulltext@MSK | Save
  • An unusual case of neuroblastoma associated OMS: High risk disease requiring immunotherapy
    Meeting Abstract

    Stiefel, J.; Khakoo, Y.; Basu, E.; Meyer, R.; Kaur, G.
    Neuro-Oncology (2019)

    Fulltext@MSK | Save
  • High-dose naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for high-risk neuroblastoma: Efficacy against histologically-evident primary refractory metastases in bone marrow
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) PLUS stepped-up dosing of granulocyte-macrophage colony-stimulating factor for neuroblastoma: Outpatient treament low immunogenicity, and major responses in a phase II trial
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Pandit-Taskar, N.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for relapsed neuroblastoma resistant to salvage therapy: A phase II trial
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Pandit-Taskar, N.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for consolidating >= 2nd complete remission of high-risk neuroblastoma
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • Clinical impact of ALK mutations in neuroblastoma
    Meeting Abstract

    O'Donohue, T.; Gulati, N.; Shukla, N.; Roberts, S.; Basu, E.; Kushner, B.; Cheung, N. K.; Modak, S.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • A curative approach to central nervous system metastases of neuroblastoma
    Meeting Abstract

    Kramer, K.; Kushner, B.; Modak, S.; Pandit-Taskar, N.; Mauguen, A.; Tomlinson, U.; Wolden, S.; Zanzonico, P.; Humm, J.; Haque, S.; more...
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • Phase 1/2 trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors
    Meeting Abstract

    Desai, A. V.; Gajjar, A.; Gauvain, K.; Basu, E. M.; Macy, M. E.; Maese, L.; Sabnis, A. J.; Foster, J.; Shusterman, S.; Yoon, J.; more...
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Preliminary results of "HITS" pilot/phase II study
    Meeting Abstract

    Modak, S.; Kushner, B.; Flores, M.; Santa-Maria, V.; Garraus, M.; Basu, E.; Roberts, S.; Castaneda, A.; Gorostegui, M.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save